Our study indicate that targeting upstream pathways that activate AKT phosphorylation, or proteins that help stabilizing AKT protein, such as Hsp70s or Hsp90, would be effective strategies for cancer therapy for patients with PTEN loss. This evidence concerns the gene AKT1 and cancer.